Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced its participation in two virtual investor conferences. The conferences include the 6th Annual Israel Conference on November 12, 2020, at 8:30 am ET, and the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 6:45 pm ET. Investors can access live webcasts of these events on Ayala's website, with archived replays available for 90 days. Ayala focuses on small molecule therapeutics for rare and aggressive cancers, with key products AL101 and AL102 targeting various tumors, supported by FDA designations.

REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Ayala management will participate in two upcoming virtual investor conferences:

• H.C. Wainwright & Co. 6^th Annual Israel Conference: Thursday, November 12, 2020 at 8:30 am ET.
• Jefferies Virtual London Healthcare Conference: Fireside chat - Thursday, November 19, 2020 at 6:45 pm ET.

A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala’s lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

What events is Ayala Pharmaceuticals participating in November 2020?

Ayala Pharmaceuticals will participate in the 6th Annual Israel Conference on November 12, 2020, and the Jefferies Virtual London Healthcare Conference on November 19, 2020.

What is the focus of Ayala Pharmaceuticals?

Ayala Pharmaceuticals focuses on developing small molecule therapeutics for rare and aggressive cancers, primarily for genetically defined patient populations.

What are the product candidates under development by Ayala Pharmaceuticals?

Ayala Pharmaceuticals is developing two main product candidates, AL101 and AL102, targeting tumors associated with the aberrant activation of the Notch pathway.

What FDA designations has Ayala's lead product AL101 received?

AL101 has received both Fast Track Designation and Orphan Drug Designation from the U.S. FDA.

How can investors access the Ayala Pharmaceuticals conference webcasts?

Investors can access the live webcasts of the conferences on Ayala's website, with replays available for 90 days after each event.